CRDL
Cardiol Therapeutics Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$2.20
+1.85%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -1.9%
- EBIT
- -5.5%
- EPS
- +27.5%
- Free cash flow
- +3.9%
- Operating cash flow
- +4.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +12.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +7.7%
- EBIT
- +14.8%
- Net income
- +7.8%
- EPS
- +23.5%
- Free cash flow
- +4.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026